Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic umbilical cord mesenchymal stem cells - Therapeutic Solutions International

Next Previous
Drug Profile

Allogeneic umbilical cord mesenchymal stem cells - Therapeutic Solutions International

Alternative Names: Allogeneic umbilical cord mesenchymal stem cells - Intravenous injection; JadiCell; JadiCells™; Mesenchymal stem cells - Therapeutic Solutions International

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jadi Cell
  • Developer Therapeutic Solutions International
  • Class Antivirals; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease
  • Preclinical Chronic obstructive pulmonary disease; Epilepsy; Idiopathic pulmonary fibrosis
  • No development reported Chronic brain damage; Traumatic brain injuries

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for preclinical development in Chronic-brain-damage in USA (IV, Injection)
  • 16 May 2024 Therapeutic Solutions International receives a notice of allowance from the United States Patent and Trademark Office regarding its patent application entitled stimulation of mesenchymal stem cell therapeutics activities by regulatory T cells
  • 05 Mar 2024 Therapeutic Solutions International plans a phase III trial for Acute respiratory distress syndrome (all-cause induced) (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top